comparemela.com

Latest Breaking News On - Prnewswire viracta therapeutics inc - Page 1 : comparemela.com

Viracta Therapeutics Announces Chief Executive Officer Leadership Succession to Drive the Next Phase of the Company s Strategic Development and Growth

/PRNewswire/ Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the succession.

United kingdomIvor roystonMark rotheraAshleigh barretoRogerj pomerantzCambridge universityHead of investor relations corporate communicationsAegerion pharmaceuticals incPrnewswire viracta therapeutics incNatural sciencesEuropean institute for business administrationViracta therapeutics incViracta therapeutic boardChief executiveChief executive officerViracta board

Viracta Therapeutics Chief Scientific Officer, Dr Ayman Elguindy, Elected to the Governing Board of the International Association for Research on Epstein-Barr Virus and Associated Diseases

/PRNewswire/ Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that the.

United statesIvor roystonAyman elguindyAshleigh barretoYale universityInternational association for research on epstein barr virusHead of investor relations corporate communicationsNational cancer instituteInternational symposiumPrnewswire viracta therapeutics incAssociation governing boardDepartment of pathologyYale university school of medicineDepartment of pediatricsViracta therapeutics incAmerican cancer society

Viracta Therapeutics Appoints Jane Chung, R Ph , to its Board of Directors

/PRNewswire/ Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the.

New yorkUnited statesColumbia universitySutro biopharmaJane chungAshleigh barretoRogerj pomerantzHead of investor relations corporate communicationsAstrazeneca pharmaceuticalsPrnewswire viracta therapeutics incGenentech incEffectiveness for onyx pharmaceuticals incJohn universityViracta therapeutics incChief commercial officerGeneral manager

Viracta Therapeutics Reports Second Quarter 2022 Financial Results and Recent Updates

Continued progress of NAVAL-1, the pivotal trial of Nana-val for the treatment of Epstein-Barr virus-positive (EBV+) lymphoma; update on the initi.

United statesSan diegoIvor roystonA dimitrios colevasAyman elguindyEzra cohenAshleigh barretoSilicon valley bankUniversity of californiaInternational association for research on epstein barr virusHead of investor relations corporate communicationsAmerican society of clinical oncologyInternational symposiumPrnewswire viracta therapeutics incScience history instituteScience history institute biotechnology heritage award

Viracta Therapeutics to Present at the Jefferies Healthcare Conference

/PRNewswire/ Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that company.

Ashleigh barretoHead of investor relations corporate communicationsPrnewswire viracta therapeutics incViracta therapeutics incJefferies healthcare conferenceViracta therapeuticsRelations contactInvestor relationsHealth care amp hospitalsMedical pharmaceuticalsTrade show news

vimarsana © 2020. All Rights Reserved.